Tag Archives: Phil Nadeau

Cowen & Co. Thinks Immunomedics’ Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Immunomedics (IMMU – Research Report) today and set a price target of $30. The company’s shares opened today at $11.87, close to its 52-week low of $11.55. According to

Cowen & Co. Sticks to Their Hold Rating for Zafgen (ZFGN)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Zafgen (ZFGN – Research Report). The company’s shares opened today at $4.98, close to its 52-week low of $4.51. According to TipRanks.com, Nadeau is

Analysts Are Bullish on Top Healthcare Stocks: Spark Therapeutics (ONCE), CytomX Therapeutics Inc (CTMX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spark Therapeutics (ONCE – Research Report), CytomX Therapeutics Inc (CTMX – Research Report) and Amgen Inc (AMGN – Research Report) with bullish

Cowen & Co. Sticks to Their Hold Rating for Regeneron (REGN)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Regeneron (REGN – Research Report), with a price target of $385. The company’s shares opened today at $396.63, close to its 52-week high of

Cowen & Co. Thinks Acorda Therapeutics’ Stock is Going to Recover

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Acorda Therapeutics (ACOR – Research Report), with a price target of $30. The company’s shares opened today at $16.50, close to its 52-week low

Analysts Offer Insights on Healthcare Companies: BioMarin (NASDAQ: BMRN), Alnylam Pharma (NASDAQ: ALNY) and Emergent Biosolutions (NYSE: EBS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin (BMRN – Research Report), Alnylam Pharma (ALNY – Research Report) and Emergent Biosolutions (EBS – Research Report). BioMarin (BMRN) Cowen & Co.